Connect with us
Stalevo
Combination
Company
Indications
- to treat patients with idiopathic Parkinson’s disease: (1) To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products. (2) To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias)